Antibiotice（ATB）株式概要Antibiotice S.A.はルーマニアで医薬品を製造・販売している。 詳細ATB ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績2/6財務の健全性5/6配当金3/6リスク分析1.66%の配当はフリーキャッシュフローで十分にカバーされていない 利益率(5%)は昨年より低い(14.6%) すべてのリスクチェックを見るATB Community Fair Values Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.NEW496,346 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG496,346 investors already sharing narrativesYour Fair ValueRON Current PriceRON 2.160.5% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture01b2016201920222025202620282031Revenue RON 1.2bEarnings RON 57.3mAdvancedSet Fair ValueView all narrativesAntibiotice S.A. 競合他社BiofarmSymbol: BVB:BIOMarket cap: RON 1.5bS.C. SintofarmSymbol: BVB:SINTMarket cap: RON 27.2mZhejiang Shengda Bio-PharmSymbol: SHSE:603079Market cap: CN¥2.2bShanXi C&Y Pharmaceutical GroupLTDSymbol: SZSE:300254Market cap: CN¥2.2b価格と性能株価の高値、安値、推移の概要Antibiotice過去の株価現在の株価RON 2.1652週高値RON 2.7352週安値RON 1.75ベータ0.241ヶ月の変化5.88%3ヶ月変化20.00%1年変化-9.05%3年間の変化209.46%5年間の変化278.95%IPOからの変化2,521.74%最新ニュースReported Earnings • May 29First quarter 2026 earnings released: EPS: RON0.019 (vs RON0.049 in 1Q 2025)First quarter 2026 results: EPS: RON0.019 (down from RON0.049 in 1Q 2025). Revenue: RON142.8m (down 13% from 1Q 2025). Net income: RON12.6m (down 62% from 1Q 2025). Profit margin: 8.8% (down from 20% in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 49% per year, which means it is well ahead of earnings.New Risk • Apr 01New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.9% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (7.8% net profit margin).Reported Earnings • Mar 30Full year 2025 earnings released: EPS: RON0.077 (vs RON0.15 in FY 2024)Full year 2025 results: EPS: RON0.077 (down from RON0.15 in FY 2024). Revenue: RON660.3m (down 4.1% from FY 2024). Net income: RON51.8m (down 49% from FY 2024). Profit margin: 7.8% (down from 15% in FY 2024). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Mar 27Antibiotice S.A. announces Annual dividend, payable on October 21, 2026Antibiotice S.A. announced Annual dividend of RON 0.0199 per share payable on October 21, 2026, ex-date on October 01, 2026 and record date on October 02, 2026.お知らせ • Jan 16+ 5 more updatesAntibiotice S.A. to Report Q1, 2026 Results on May 27, 2026Antibiotice S.A. announced that they will report Q1, 2026 results on May 27, 2026Reported Earnings • Nov 15Third quarter 2025 earnings released: RON0.025 loss per share (vs RON0.021 profit in 3Q 2024)Third quarter 2025 results: RON0.025 loss per share (down from RON0.021 profit in 3Q 2024). Revenue: RON137.2m (down 13% from 3Q 2024). Net loss: RON16.5m (down 220% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.最新情報をもっと見るRecent updatesReported Earnings • May 29First quarter 2026 earnings released: EPS: RON0.019 (vs RON0.049 in 1Q 2025)First quarter 2026 results: EPS: RON0.019 (down from RON0.049 in 1Q 2025). Revenue: RON142.8m (down 13% from 1Q 2025). Net income: RON12.6m (down 62% from 1Q 2025). Profit margin: 8.8% (down from 20% in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 49% per year, which means it is well ahead of earnings.New Risk • Apr 01New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.9% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (7.8% net profit margin).Reported Earnings • Mar 30Full year 2025 earnings released: EPS: RON0.077 (vs RON0.15 in FY 2024)Full year 2025 results: EPS: RON0.077 (down from RON0.15 in FY 2024). Revenue: RON660.3m (down 4.1% from FY 2024). Net income: RON51.8m (down 49% from FY 2024). Profit margin: 7.8% (down from 15% in FY 2024). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Mar 27Antibiotice S.A. announces Annual dividend, payable on October 21, 2026Antibiotice S.A. announced Annual dividend of RON 0.0199 per share payable on October 21, 2026, ex-date on October 01, 2026 and record date on October 02, 2026.お知らせ • Jan 16+ 5 more updatesAntibiotice S.A. to Report Q1, 2026 Results on May 27, 2026Antibiotice S.A. announced that they will report Q1, 2026 results on May 27, 2026Reported Earnings • Nov 15Third quarter 2025 earnings released: RON0.025 loss per share (vs RON0.021 profit in 3Q 2024)Third quarter 2025 results: RON0.025 loss per share (down from RON0.021 profit in 3Q 2024). Revenue: RON137.2m (down 13% from 3Q 2024). Net loss: RON16.5m (down 220% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Sep 18Upcoming dividend of RON0.021 per shareEligible shareholders must have bought the stock before 25 September 2025. Payment date: 08 October 2025. Payout ratio is a comfortable 16% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of Romanian dividend payers (6.3%). Lower than average of industry peers (2.9%).New Risk • Aug 17New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 1.9% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. This is currently the only risk that has been identified for the company.Reported Earnings • Aug 17Second quarter 2025 earnings released: EPS: RON0.039 (vs RON0.055 in 2Q 2024)Second quarter 2025 results: EPS: RON0.039 (down from RON0.055 in 2Q 2024). Revenue: RON175.8m (up 1.8% from 2Q 2024). Net income: RON26.5m (down 28% from 2Q 2024). Profit margin: 15% (down from 21% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Jun 06Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON2.44, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 362% over the past three years.Valuation Update With 7 Day Price Move • May 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON2.11, the stock trades at a trailing P/E ratio of 14.5x. Average trailing P/E is 23x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 309% over the past three years.Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. 2 independent directors (4 non-independent directors). GM, General Director & Chairman Ioan Nani is the most experienced director on the board, commencing their role in 2009. Non Independent Director Ionut-Sebastian Iavor was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.分析記事 • Apr 25Antibiotice (BVB:ATB) Is Paying Out Less In Dividends Than Last YearAntibiotice S.A.'s ( BVB:ATB ) dividend is being reduced by 75% to RON0.0206 per share on 8th of October, in comparison...分析記事 • Apr 04Antibiotice (BVB:ATB) Will Pay A Smaller Dividend Than Last YearThe board of Antibiotice S.A. ( BVB:ATB ) has announced that the dividend on 8th of October will be reduced by 75% from...Declared Dividend • Apr 03Dividend reduced to RON0.021Dividend of RON0.021 is 75% lower than last year. Ex-date: 25th September 2025 Payment date: 8th October 2025 Dividend yield will be 0.9%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (60% earnings payout ratio) but not covered by cash flows (127% cash payout ratio). The dividend has increased by an average of 14% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 26% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.New Risk • Mar 12New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 150% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 150% per year for the foreseeable future. Minor Risk Dividend is not well covered by cash flows (127% cash payout ratio).Reported Earnings • Mar 02Full year 2024 earnings released: EPS: RON0.15 (vs RON0.12 in FY 2023)Full year 2024 results: EPS: RON0.15 (up from RON0.12 in FY 2023). Revenue: RON688.9m (up 12% from FY 2023). Net income: RON99.4m (up 23% from FY 2023). Profit margin: 14% (up from 13% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 69% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Feb 25Antibiotice S.A., Annual General Meeting, Mar 28, 2025Antibiotice S.A., Annual General Meeting, Mar 28, 2025, at 10:00 E. Europe Standard Time. Location: at the company`s headquarters in the municipality, of iasi, str. valea lupului nr. 1, Romania分析記事 • Nov 23Is Antibiotice (BVB:ATB) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...New Risk • Nov 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 3.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (156% cash payout ratio). Share price has been volatile over the past 3 months (3.5% average weekly change).Valuation Update With 7 Day Price Move • Nov 22Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to RON2.76, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 405% over the past three years.Upcoming Dividend • Sep 16Upcoming dividend of RON0.083 per shareEligible shareholders must have bought the stock before 23 September 2024. Payment date: 11 October 2024. Payout ratio is a comfortable 60% and this is well supported by cash flows. Trailing yield: 2.7%. Lower than top quartile of Romanian dividend payers (7.0%). Higher than average of industry peers (2.2%).Reported Earnings • Aug 20Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: RON172.7m (up 22% from 2Q 2023). Net income: RON36.9m (down 7.3% from 2Q 2023). Profit margin: 21% (down from 28% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Aug 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Romanian stocks, typically moving 8.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.Buy Or Sell Opportunity • Aug 05Now 20% undervaluedOver the last 90 days, the stock has risen 36% to RON2.67. The fair value is estimated to be RON3.36, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 49%.Valuation Update With 7 Day Price Move • Jun 18Investor sentiment improves as stock rises 21%After last week's 21% share price gain to RON3.14, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 25x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 475% over the past three years.分析記事 • Jun 07Market Might Still Lack Some Conviction On Antibiotice S.A. (BVB:ATB) Even After 25% Share Price BoostDespite an already strong run, Antibiotice S.A. ( BVB:ATB ) shares have been powering on, with a gain of 25% in the...New Risk • Jun 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Jun 06Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON2.49, the stock trades at a trailing P/E ratio of 17.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 351% over the past three years.Reported Earnings • May 19First quarter 2024 earnings released: EPS: RON0.056 (vs RON0.033 in 1Q 2023)First quarter 2024 results: EPS: RON0.056 (up from RON0.033 in 1Q 2023). Revenue: RON186.0m (up 2.2% from 1Q 2023). Net income: RON37.3m (up 68% from 1Q 2023). Profit margin: 20% (up from 12% in 1Q 2023). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 47% per year whereas the company’s share price has increased by 52% per year.Reported Earnings • Apr 22Full year 2023 earnings released: EPS: RON0.12 (vs RON0.077 in FY 2022)Full year 2023 results: EPS: RON0.12 (up from RON0.077 in FY 2022). Revenue: RON615.3m (up 22% from FY 2022). Net income: RON81.1m (up 57% from FY 2022). Profit margin: 13% (up from 10% in FY 2022). The increase in margin was driven by higher revenue. Post-clinical trial products Launched (during full year): 3 Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Apr 05Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non Executive Chairman Lucian Timofticiuc was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Mar 21New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 296% Dividend yield: 2.7% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (296% cash payout ratio). Share price has been volatile over the past 3 months (5.3% average weekly change).分析記事 • Jan 30Antibiotice S.A. (BVB:ATB) Looks Just Right With A 26% Price JumpDespite an already strong run, Antibiotice S.A. ( BVB:ATB ) shares have been powering on, with a gain of 26% in the...お知らせ • Jan 30+ 5 more updatesAntibiotice S.A. to Report Fiscal Year 2023 Results on Feb 28, 2024Antibiotice S.A. announced that they will report fiscal year 2023 results on Feb 28, 2024Valuation Update With 7 Day Price Move • Jan 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to RON1.64, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 23x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 238% over the past three years.分析記事 • Jan 13We Think Antibiotice (BVB:ATB) Can Manage Its Debt With EaseLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Nov 17Third quarter 2023 earnings released: EPS: RON0.022 (vs RON0.009 in 3Q 2022)Third quarter 2023 results: EPS: RON0.022 (up from RON0.009 in 3Q 2022). Revenue: RON150.7m (up 28% from 3Q 2022). Net income: RON14.7m (up 133% from 3Q 2022). Profit margin: 9.8% (up from 5.4% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Nov 16Investor sentiment improves as stock rises 16%After last week's 16% share price gain to RON1.39, the stock trades at a trailing P/E ratio of 14x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 189% over the past three years.Valuation Update With 7 Day Price Move • Sep 19Investor sentiment improves as stock rises 15%After last week's 15% share price gain to RON1.02, the stock trades at a trailing P/E ratio of 10.2x. Average trailing P/E is 25x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 97% over the past three years.分析記事 • Aug 16These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt SafelyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Jan 17+ 4 more updatesAntibiotice S.A. to Report Fiscal Year 2022 Results on Feb 24, 2023Antibiotice S.A. announced that they will report fiscal year 2022 results on Feb 24, 2023Board Change • Nov 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. GM, Vice Chairman & Non-Independent Executive Director Ioan Nani is the most experienced director on the board, commencing their role in 2009. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Board Change • Apr 27High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. GM & Non-Independent Executive Director Ioan Nani is the most experienced director on the board, commencing their role in 2009. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 12Third quarter 2021 earnings released: RON0.002 loss per share (vs RON0.002 loss in 3Q 2020)The company reported a solid third quarter result with improved revenues and control over costs, although losses were not reduced. Third quarter 2021 results: Revenue: RON122.4m (up 108% from 3Q 2020). Net loss: RON1.10m (flat on 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.Reported Earnings • Jul 28Second quarter 2021 earnings released: EPS RON0.023 (vs RON0.022 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: RON121.5m (up 61% from 2Q 2020). Net income: RON15.3m (up 1.5% from 2Q 2020). Profit margin: 13% (down from 20% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.分析記事 • Jun 08Is Antibiotice (BVB:ATB) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • May 14First quarter 2021 earnings released: EPS RON0.006 (vs RON0.006 in 1Q 2020)The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: RON82.3m (up 10% from 1Q 2020). Net income: RON4.04m (down 1.0% from 1Q 2020). Profit margin: 4.9% (down from 5.5% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.分析記事 • Mar 10These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt ExtensivelyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Feb 28Full year 2020 earnings released: EPS RON0.037 (vs RON0.046 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: RON382.8m (down 3.1% from FY 2019). Net income: RON25.1m (down 19% from FY 2019). Profit margin: 6.5% (down from 7.8% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.分析記事 • Feb 11Tread With Caution Around Antibiotice S.A.'s (BVB:ATB) 5.8% Dividend YieldToday we'll take a closer look at Antibiotice S.A. ( BVB:ATB ) from a dividend investor's perspective. Owning a strong...Is New 90 Day High Low • Jan 27New 90-day high: RON0.52The company is up 4.0% from its price of RON0.49 on 29 October 2020. The Romanian market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 9.0% over the same period.分析記事 • Jan 12Calculating The Intrinsic Value Of Antibiotice S.A. (BVB:ATB)Does the January share price for Antibiotice S.A. ( BVB:ATB ) reflect what it's really worth? Today, we will estimate...分析記事 • Dec 16Are Antibiotice's (BVB:ATB) Statutory Earnings A Good Guide To Its Underlying Profitability?Broadly speaking, profitable businesses are less risky than unprofitable ones. Having said that, sometimes statutory...分析記事 • Nov 24Is Antibiotice (BVB:ATB) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Is New 90 Day High Low • Nov 20New 90-day low: RON0.49The company is down 9.0% from its price of RON0.54 on 21 August 2020. The Romanian market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period.Reported Earnings • Nov 14Third quarter 2020 earnings released: RON0.002 loss per shareThe company reported a soft third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: RON87.6m (up 23% from 3Q 2019). Net loss: RON1.10m (loss widened 46% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 4% per year.Is New 90 Day High Low • Sep 18New 90-day low: RON0.52The company is down 3.0% from its price of RON0.53 on 19 June 2020. The Romanian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period.株主還元ATBRO PharmaceuticalsRO 市場7D2.1%1.8%7.6%1Y-9.1%18.9%74.8%株主還元を見る業界別リターン: ATB過去 1 年間で18.9 % の収益を上げたRO Pharmaceuticals業界を下回りました。リターン対市場: ATBは、過去 1 年間で74.8 % のリターンを上げたRO市場を下回りました。価格変動Is ATB's price volatile compared to industry and market?ATB volatilityATB Average Weekly Movement4.0%Pharmaceuticals Industry Average Movement5.3%Market Average Movement4.6%10% most volatile stocks in RO Market12.6%10% least volatile stocks in RO Market2.8%安定した株価: ATB 、 RO市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: ATBの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19551,355Ioan Naniwww.antibiotice.roAntibiotice S.A.はルーマニアで医薬品を製造・販売している。同社は、結核治療薬を含む抗感染症薬、心臓血管薬、消化管・代謝クラス、婦人科疾患治療用製剤、皮膚科・中枢神経系製剤からなるジェネリック処方薬、食品サプリメント、化粧品、医療機器を含むジェネリック非処方薬、活性物質、生物肥料、動物用医薬品を提供している。製品は無菌の注射用粉末剤、カプセル剤、錠剤、軟膏剤、ゲル剤、クリーム剤、坐剤などの形態で提供されている。また、原薬も提供している。また、世界中に製品を輸出している。Antibiotice S.A.は1955年に設立され、ルーマニアのイアシに本社を置く。もっと見るAntibiotice S.A. 基礎のまとめAntibiotice の収益と売上を時価総額と比較するとどうか。ATB 基礎統計学時価総額RON 1.45b収益（TTM）RON 31.69m売上高(TTM)RON 638.98m45.8xPER（株価収益率2.3xP/SレシオATB は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ATB 損益計算書（TTM）収益RON 638.98m売上原価RON 259.48m売上総利益RON 379.50mその他の費用RON 347.81m収益RON 31.69m直近の収益報告Mar 31, 2026次回決算日Aug 17, 2026一株当たり利益（EPS）0.047グロス・マージン59.39%純利益率4.96%有利子負債／自己資本比率33.2%ATB の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.7%現在の配当利回り76%配当性向ATB 配当は確実ですか？ATB 配当履歴とベンチマークを見るATB 、いつまでに購入すれば配当金を受け取れますか？Antibiotice 配当日配当落ち日Oct 01 2026配当支払日Oct 21 2026配当落ちまでの日数87 days配当支払日までの日数107 daysATB 配当は確実ですか？ATB 配当履歴とベンチマークを見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/05 22:18終値2026/07/03 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Antibiotice S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Vladimira UrbankovaErste Group Bank AGDaniela MandruSwiss Capital SAAndrei RadulescuSwiss Capital SA
Reported Earnings • May 29First quarter 2026 earnings released: EPS: RON0.019 (vs RON0.049 in 1Q 2025)First quarter 2026 results: EPS: RON0.019 (down from RON0.049 in 1Q 2025). Revenue: RON142.8m (down 13% from 1Q 2025). Net income: RON12.6m (down 62% from 1Q 2025). Profit margin: 8.8% (down from 20% in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 49% per year, which means it is well ahead of earnings.
New Risk • Apr 01New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.9% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (7.8% net profit margin).
Reported Earnings • Mar 30Full year 2025 earnings released: EPS: RON0.077 (vs RON0.15 in FY 2024)Full year 2025 results: EPS: RON0.077 (down from RON0.15 in FY 2024). Revenue: RON660.3m (down 4.1% from FY 2024). Net income: RON51.8m (down 49% from FY 2024). Profit margin: 7.8% (down from 15% in FY 2024). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Mar 27Antibiotice S.A. announces Annual dividend, payable on October 21, 2026Antibiotice S.A. announced Annual dividend of RON 0.0199 per share payable on October 21, 2026, ex-date on October 01, 2026 and record date on October 02, 2026.
お知らせ • Jan 16+ 5 more updatesAntibiotice S.A. to Report Q1, 2026 Results on May 27, 2026Antibiotice S.A. announced that they will report Q1, 2026 results on May 27, 2026
Reported Earnings • Nov 15Third quarter 2025 earnings released: RON0.025 loss per share (vs RON0.021 profit in 3Q 2024)Third quarter 2025 results: RON0.025 loss per share (down from RON0.021 profit in 3Q 2024). Revenue: RON137.2m (down 13% from 3Q 2024). Net loss: RON16.5m (down 220% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • May 29First quarter 2026 earnings released: EPS: RON0.019 (vs RON0.049 in 1Q 2025)First quarter 2026 results: EPS: RON0.019 (down from RON0.049 in 1Q 2025). Revenue: RON142.8m (down 13% from 1Q 2025). Net income: RON12.6m (down 62% from 1Q 2025). Profit margin: 8.8% (down from 20% in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 49% per year, which means it is well ahead of earnings.
New Risk • Apr 01New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.9% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (7.8% net profit margin).
Reported Earnings • Mar 30Full year 2025 earnings released: EPS: RON0.077 (vs RON0.15 in FY 2024)Full year 2025 results: EPS: RON0.077 (down from RON0.15 in FY 2024). Revenue: RON660.3m (down 4.1% from FY 2024). Net income: RON51.8m (down 49% from FY 2024). Profit margin: 7.8% (down from 15% in FY 2024). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Mar 27Antibiotice S.A. announces Annual dividend, payable on October 21, 2026Antibiotice S.A. announced Annual dividend of RON 0.0199 per share payable on October 21, 2026, ex-date on October 01, 2026 and record date on October 02, 2026.
お知らせ • Jan 16+ 5 more updatesAntibiotice S.A. to Report Q1, 2026 Results on May 27, 2026Antibiotice S.A. announced that they will report Q1, 2026 results on May 27, 2026
Reported Earnings • Nov 15Third quarter 2025 earnings released: RON0.025 loss per share (vs RON0.021 profit in 3Q 2024)Third quarter 2025 results: RON0.025 loss per share (down from RON0.021 profit in 3Q 2024). Revenue: RON137.2m (down 13% from 3Q 2024). Net loss: RON16.5m (down 220% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Sep 18Upcoming dividend of RON0.021 per shareEligible shareholders must have bought the stock before 25 September 2025. Payment date: 08 October 2025. Payout ratio is a comfortable 16% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of Romanian dividend payers (6.3%). Lower than average of industry peers (2.9%).
New Risk • Aug 17New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 1.9% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. This is currently the only risk that has been identified for the company.
Reported Earnings • Aug 17Second quarter 2025 earnings released: EPS: RON0.039 (vs RON0.055 in 2Q 2024)Second quarter 2025 results: EPS: RON0.039 (down from RON0.055 in 2Q 2024). Revenue: RON175.8m (up 1.8% from 2Q 2024). Net income: RON26.5m (down 28% from 2Q 2024). Profit margin: 15% (down from 21% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Jun 06Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON2.44, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 362% over the past three years.
Valuation Update With 7 Day Price Move • May 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON2.11, the stock trades at a trailing P/E ratio of 14.5x. Average trailing P/E is 23x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 309% over the past three years.
Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. 2 independent directors (4 non-independent directors). GM, General Director & Chairman Ioan Nani is the most experienced director on the board, commencing their role in 2009. Non Independent Director Ionut-Sebastian Iavor was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
分析記事 • Apr 25Antibiotice (BVB:ATB) Is Paying Out Less In Dividends Than Last YearAntibiotice S.A.'s ( BVB:ATB ) dividend is being reduced by 75% to RON0.0206 per share on 8th of October, in comparison...
分析記事 • Apr 04Antibiotice (BVB:ATB) Will Pay A Smaller Dividend Than Last YearThe board of Antibiotice S.A. ( BVB:ATB ) has announced that the dividend on 8th of October will be reduced by 75% from...
Declared Dividend • Apr 03Dividend reduced to RON0.021Dividend of RON0.021 is 75% lower than last year. Ex-date: 25th September 2025 Payment date: 8th October 2025 Dividend yield will be 0.9%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (60% earnings payout ratio) but not covered by cash flows (127% cash payout ratio). The dividend has increased by an average of 14% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 26% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
New Risk • Mar 12New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 150% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 150% per year for the foreseeable future. Minor Risk Dividend is not well covered by cash flows (127% cash payout ratio).
Reported Earnings • Mar 02Full year 2024 earnings released: EPS: RON0.15 (vs RON0.12 in FY 2023)Full year 2024 results: EPS: RON0.15 (up from RON0.12 in FY 2023). Revenue: RON688.9m (up 12% from FY 2023). Net income: RON99.4m (up 23% from FY 2023). Profit margin: 14% (up from 13% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 69% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Feb 25Antibiotice S.A., Annual General Meeting, Mar 28, 2025Antibiotice S.A., Annual General Meeting, Mar 28, 2025, at 10:00 E. Europe Standard Time. Location: at the company`s headquarters in the municipality, of iasi, str. valea lupului nr. 1, Romania
分析記事 • Nov 23Is Antibiotice (BVB:ATB) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
New Risk • Nov 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 3.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (156% cash payout ratio). Share price has been volatile over the past 3 months (3.5% average weekly change).
Valuation Update With 7 Day Price Move • Nov 22Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to RON2.76, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 405% over the past three years.
Upcoming Dividend • Sep 16Upcoming dividend of RON0.083 per shareEligible shareholders must have bought the stock before 23 September 2024. Payment date: 11 October 2024. Payout ratio is a comfortable 60% and this is well supported by cash flows. Trailing yield: 2.7%. Lower than top quartile of Romanian dividend payers (7.0%). Higher than average of industry peers (2.2%).
Reported Earnings • Aug 20Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: RON172.7m (up 22% from 2Q 2023). Net income: RON36.9m (down 7.3% from 2Q 2023). Profit margin: 21% (down from 28% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Aug 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Romanian stocks, typically moving 8.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
Buy Or Sell Opportunity • Aug 05Now 20% undervaluedOver the last 90 days, the stock has risen 36% to RON2.67. The fair value is estimated to be RON3.36, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 49%.
Valuation Update With 7 Day Price Move • Jun 18Investor sentiment improves as stock rises 21%After last week's 21% share price gain to RON3.14, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 25x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 475% over the past three years.
分析記事 • Jun 07Market Might Still Lack Some Conviction On Antibiotice S.A. (BVB:ATB) Even After 25% Share Price BoostDespite an already strong run, Antibiotice S.A. ( BVB:ATB ) shares have been powering on, with a gain of 25% in the...
New Risk • Jun 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Jun 06Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON2.49, the stock trades at a trailing P/E ratio of 17.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 351% over the past three years.
Reported Earnings • May 19First quarter 2024 earnings released: EPS: RON0.056 (vs RON0.033 in 1Q 2023)First quarter 2024 results: EPS: RON0.056 (up from RON0.033 in 1Q 2023). Revenue: RON186.0m (up 2.2% from 1Q 2023). Net income: RON37.3m (up 68% from 1Q 2023). Profit margin: 20% (up from 12% in 1Q 2023). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 47% per year whereas the company’s share price has increased by 52% per year.
Reported Earnings • Apr 22Full year 2023 earnings released: EPS: RON0.12 (vs RON0.077 in FY 2022)Full year 2023 results: EPS: RON0.12 (up from RON0.077 in FY 2022). Revenue: RON615.3m (up 22% from FY 2022). Net income: RON81.1m (up 57% from FY 2022). Profit margin: 13% (up from 10% in FY 2022). The increase in margin was driven by higher revenue. Post-clinical trial products Launched (during full year): 3 Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Apr 05Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non Executive Chairman Lucian Timofticiuc was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Mar 21New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 296% Dividend yield: 2.7% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (296% cash payout ratio). Share price has been volatile over the past 3 months (5.3% average weekly change).
分析記事 • Jan 30Antibiotice S.A. (BVB:ATB) Looks Just Right With A 26% Price JumpDespite an already strong run, Antibiotice S.A. ( BVB:ATB ) shares have been powering on, with a gain of 26% in the...
お知らせ • Jan 30+ 5 more updatesAntibiotice S.A. to Report Fiscal Year 2023 Results on Feb 28, 2024Antibiotice S.A. announced that they will report fiscal year 2023 results on Feb 28, 2024
Valuation Update With 7 Day Price Move • Jan 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to RON1.64, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 23x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 238% over the past three years.
分析記事 • Jan 13We Think Antibiotice (BVB:ATB) Can Manage Its Debt With EaseLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Nov 17Third quarter 2023 earnings released: EPS: RON0.022 (vs RON0.009 in 3Q 2022)Third quarter 2023 results: EPS: RON0.022 (up from RON0.009 in 3Q 2022). Revenue: RON150.7m (up 28% from 3Q 2022). Net income: RON14.7m (up 133% from 3Q 2022). Profit margin: 9.8% (up from 5.4% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Nov 16Investor sentiment improves as stock rises 16%After last week's 16% share price gain to RON1.39, the stock trades at a trailing P/E ratio of 14x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 189% over the past three years.
Valuation Update With 7 Day Price Move • Sep 19Investor sentiment improves as stock rises 15%After last week's 15% share price gain to RON1.02, the stock trades at a trailing P/E ratio of 10.2x. Average trailing P/E is 25x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 97% over the past three years.
分析記事 • Aug 16These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt SafelyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Jan 17+ 4 more updatesAntibiotice S.A. to Report Fiscal Year 2022 Results on Feb 24, 2023Antibiotice S.A. announced that they will report fiscal year 2022 results on Feb 24, 2023
Board Change • Nov 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. GM, Vice Chairman & Non-Independent Executive Director Ioan Nani is the most experienced director on the board, commencing their role in 2009. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Board Change • Apr 27High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. GM & Non-Independent Executive Director Ioan Nani is the most experienced director on the board, commencing their role in 2009. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 12Third quarter 2021 earnings released: RON0.002 loss per share (vs RON0.002 loss in 3Q 2020)The company reported a solid third quarter result with improved revenues and control over costs, although losses were not reduced. Third quarter 2021 results: Revenue: RON122.4m (up 108% from 3Q 2020). Net loss: RON1.10m (flat on 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
Reported Earnings • Jul 28Second quarter 2021 earnings released: EPS RON0.023 (vs RON0.022 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: RON121.5m (up 61% from 2Q 2020). Net income: RON15.3m (up 1.5% from 2Q 2020). Profit margin: 13% (down from 20% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
分析記事 • Jun 08Is Antibiotice (BVB:ATB) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • May 14First quarter 2021 earnings released: EPS RON0.006 (vs RON0.006 in 1Q 2020)The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: RON82.3m (up 10% from 1Q 2020). Net income: RON4.04m (down 1.0% from 1Q 2020). Profit margin: 4.9% (down from 5.5% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
分析記事 • Mar 10These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt ExtensivelyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Feb 28Full year 2020 earnings released: EPS RON0.037 (vs RON0.046 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: RON382.8m (down 3.1% from FY 2019). Net income: RON25.1m (down 19% from FY 2019). Profit margin: 6.5% (down from 7.8% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
分析記事 • Feb 11Tread With Caution Around Antibiotice S.A.'s (BVB:ATB) 5.8% Dividend YieldToday we'll take a closer look at Antibiotice S.A. ( BVB:ATB ) from a dividend investor's perspective. Owning a strong...
Is New 90 Day High Low • Jan 27New 90-day high: RON0.52The company is up 4.0% from its price of RON0.49 on 29 October 2020. The Romanian market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 9.0% over the same period.
分析記事 • Jan 12Calculating The Intrinsic Value Of Antibiotice S.A. (BVB:ATB)Does the January share price for Antibiotice S.A. ( BVB:ATB ) reflect what it's really worth? Today, we will estimate...
分析記事 • Dec 16Are Antibiotice's (BVB:ATB) Statutory Earnings A Good Guide To Its Underlying Profitability?Broadly speaking, profitable businesses are less risky than unprofitable ones. Having said that, sometimes statutory...
分析記事 • Nov 24Is Antibiotice (BVB:ATB) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Is New 90 Day High Low • Nov 20New 90-day low: RON0.49The company is down 9.0% from its price of RON0.54 on 21 August 2020. The Romanian market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period.
Reported Earnings • Nov 14Third quarter 2020 earnings released: RON0.002 loss per shareThe company reported a soft third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: RON87.6m (up 23% from 3Q 2019). Net loss: RON1.10m (loss widened 46% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 4% per year.
Is New 90 Day High Low • Sep 18New 90-day low: RON0.52The company is down 3.0% from its price of RON0.53 on 19 June 2020. The Romanian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period.
